Steven C. Griffen, MD

OMass Therapeutics
Oxford, United Kingdom

Disclosure information not submitted.

Presentation(s):

• SUN-463 - Development of A Quantitative Systems Pharmacology Model to Investigate the Influence of Melanocortin-2 Receptor Antagonist Residence Time in the Treatment of Congenital Adrenal Hyperplasia

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT